ICLR

ICONF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$125.00

Analysis reference price unavailable

Analysis 2026-04-29 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$108.00

Analysis reference price unavailable

Analysis 2026-04-29 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$85.00

Analysis reference price unavailable

Analysis 2026-04-29 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

This is still a monitoring-style T+1 earnings follow-up rather than a clean post-print upgrade. News tone improved sharply on April 29, 2026 because the investigation concluded and the quantified overstatement was below the prior ceiling, but the move also looks like a relief rally after a severe February credibility shock. Headline buzz is high, while post-print analyst revision and target-change evidence was not available in the checked sources, which keeps confidence low despite the positive same-day price reaction.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-29catalystRelief rally after investigation completion may fade without clean filing follow-throughMedium impact

Shares were 116.17 USD at 20:15 UTC on April 29, 2026 versus the April 28 anchor close of 102.49 USD, a roughly 13.3% rebound after the company reaffirmed no customer, operational, or cash-flow impact from the accounting issues [#PR-2026-04-29].

2026-05-31eventAudited 2025 results and Form 20-F filing remain the key de-risking eventHigh impact

Management said the audit committee investigation is complete, revenue overstatements in 2023-2024 were below the previously disclosed 2% upper bound, 2025 impact was smaller, and the company expects to complete the external audit and file its Form 20-F in the coming weeks, including material-weakness remediation detail [#PR-2026-04-29].

2026-09-30catalystAdvarra partnership is a real operating lever, but proof needs backlog and win-rate evidenceMedium impact

ICON and Advarra announced a definitive partnership on March 24, 2026 to create a connected site-network model intended to reduce administrative friction, accelerate study startup, and improve participation; this is strategically relevant, but equity impact likely depends on later proof in bookings, cancellations, and backlog conversion [#PR-2026-03-24].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology